Where Were the Women? Gender Parity in Clinical Trials | NEJM
Perspective from The New England Journal of Medicine — Where Were the Women? Gender Parity in Clinical Trials
Perspective from The New England Journal of Medicine — Where Were the Women? Gender Parity in Clinical Trials
This year’s HCC Day on the 27th February 2025 will take place in Bern, Switzerland and can be joined online as well. If you want…
Balancing anticancer therapy efficacy and safety in advanced hepatocellular carcinoma: a case report
HCC prevalence and etiology differ between African regions. To better understand these differences, a survey was conducted to characterize the health care practices in HCC…
Le BVGH et l’AORTIC organiseront une série de 11 sessions de conférences numériques de l’African Access Initiative (AAI) pour informer les professionnels de santé primaires…
4114Background: Gallbladder cancer (GBC) is a molecularly distinct entity among biliary tract tumors. ERBB2 amplification and mutation have been described in GBC, however, clinical and…
Abstract. Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER…
In the global, phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) improved overall survival (OS) vs. sorafenib; durvalumab…
The Asia-Pacific Primary Liver Cancer Expert (APPLE) Association was established in 2013. The main objective of the association is to promote the scientific advancement of…
The Asia-Pacific Primary Liver Cancer Expert (APPLE) Association was established in 2013. The main objective of the association is to promote the scientific advancement of…